Japanese Journal of Ophthalmology, published by Springer Japan KK, is a premier peer-reviewed journal dedicated to advancing the field of ophthalmology. With an impressive impact reflected in its Q1 categories—ranking among the top journals in both Medicine (miscellaneous) and Ophthalmology, as per the 2023 metrics—it serves as an essential platform for researchers and professionals to disseminate their findings. Covering a broad spectrum of topics from clinical studies to innovative technologies in eye care, this journal not only supports the ongoing education of its readership but also fosters significant developments within the field. The journal, which has been in circulation since 1973 and is set to continue through 2024, offers access to vital research, thereby enabling practitioners and scholars to keep abreast of the latest advancements. Its distinguished Scopus ranking of #30 out of 137 in Medicine - Ophthalmology, placing it in the 78th percentile, further underscores its influence and importance in contributing to the global understanding of eye health.

BMC Ophthalmology is a premier open access journal dedicated to advancing the field of ophthalmology through the publication of high-quality, peer-reviewed research. Published by BMC in the United Kingdom, this journal has been a vital resource since its inception in 2001 and continuously contributes to the global dialogue in vision science. With an impact factor reflecting its growing influence, BMC Ophthalmology is ranked among the top quartiles (Q2) in both general medicine and ophthalmology, emphasizing its significance in medical research. The journal encourages submissions that explore innovative diagnostics, treatment approaches, and understandings of various ocular diseases, thereby appealing to researchers, clinicians, and students alike. As an open access platform, it ensures that cutting-edge research is not only published but also readily accessible to a worldwide audience, promoting further study and collaboration in this essential area of medicine.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

Investigative Ophthalmology & Visual Science (IOVS) is a leading academic journal published by the Association for Research in Vision and Ophthalmology, dedicated to advancing the field of ophthalmology and visual science. With an impressive impact factor and ranking in the Q1 category for both Ophthalmology and Sensory Systems, IOVS is well-respected for disseminating cutting-edge research and innovative discoveries. Established in 1977, this Open Access journal allows for broad accessibility to pioneering studies, fostering collaboration among researchers, clinicians, and students. The journal has consistently maintained high visibility in the academic community, evidenced by its robust rankings in Scopus, including Rank #16 in Ophthalmology. As it continues to pave the way for future developments in the understanding and treatment of ocular diseases, IOVS serves as an invaluable resource for those immersed in the complex field of visual science.

SURVEY OF OPHTHALMOLOGY is a premier journal published by Elsevier Science Inc, dedicated to advancing knowledge in the field of ophthalmology. With an impact factor reflective of its high-quality research—ranking 7th out of 137 in the Scopus category for medicine and ophthalmology, this journal maintains a prestigious Q1 categorization in its field for 2023. Since its inception in 1956, the journal has provided comprehensive reviews and original articles covering various aspects of ophthalmic research and clinical practice, supporting the ongoing education of researchers, professionals, and students alike. While open access options are not available, the journal remains an essential resource for the latest developments, discoveries, and expert insights that shape the future of eye health. Based in the United States, at STE 800, 230 Park Ave, New York, NY 10169, the journal continues a legacy of excellence in ophthalmology until 2024 and beyond, making it a pivotal element of scholarly discourse in this vital medical discipline.

Translational Vision Science & Technology is a premier open access journal dedicated to the advancement of the field of ophthalmology and biomedical engineering. Published by the Association for Research in Vision and Ophthalmology, Inc., this journal has established itself as a leading source of high-quality research since its inception in 2013, achieving a remarkable impact factor reflective of its influential contribution to the field. With an impressive ranking of #21 in Ophthalmology and #120 in Biomedical Engineering within the Scopus database, it sits within the prestigious Q1 quartile for both categories as of 2023, further validating its significance. The journal's scope encompasses a wide variety of topics focused on the intersection of ophthalmological science and technological innovation, welcoming contributions that promote the understanding and treatment of visual disorders. Available as an Open Access publication since 2016, it ensures that cutting-edge research is freely accessible to researchers, practitioners, and students worldwide, facilitating the rapid dissemination of knowledge essential for the advancement of vision science.

Saudi Journal of Ophthalmology, published by Wolters Kluwer Medknow Publications, stands as a crucial platform for the dissemination of innovative research and clinical practices in the field of ophthalmology. Since its inception in 2009, this journal has effectively contributed to the growing body of knowledge with a focus on addressing the diverse visual health challenges faced globally. With an ISSN of 1319-4534 and a E-ISSN of 2542-6680, the journal is indexed in Scopus, where it ranks in the Q3 category of ophthalmology, reflecting its commitment to quality research despite the competitive landscape. Situated in India, it provides a unique regional perspective while facilitating global discourse among researchers, practitioners, and students in ophthalmological sciences. Although it currently does not operate as an open-access journal, the Saudi Journal of Ophthalmology is essential for those aiming to expand their understanding of advancements in eye care, making it a valuable resource for professionals dedicated to enhancing patient outcomes through informed research and clinical practice.

JOURNAL FRANCAIS D OPHTALMOLOGIE, published by MASSON EDITEUR, is a prominent peer-reviewed journal that serves as a vital resource in the field of ophthalmology. Launched in 1978, this esteemed publication continues to make significant contributions to the advancement of ocular health and vision science, with its scope encompassing clinical practices, innovative research, and the latest technological advancements in ophthalmic care. Based in France, the journal is recognized in the 2023 category quartiles with a Q3 ranking in ophthalmology, reflecting its dedication to quality scholarship within a competitive landscape, as evidenced by its positioning in the 30th percentile of the Scopus rankings. While it operates without Open Access, the journal remains crucial for professionals, researchers, and students alike, providing a platform for sharing knowledge and fostering collaborations in the global ophthalmological community.

MOLECULAR VISION is a premier open-access journal that has been advancing the field of ophthalmology since its inception in 1995. Published by MOLECULAR VISION, this journal boasts a strong reputation, currently ranking in the second quartile (Q2) of its category, with a Scopus ranking of 35 out of 137, placing it in the 74th percentile among peer publications. Dedicated to disseminating groundbreaking research and innovative findings in the study of vision and ocular health, MOLECULAR VISION serves as a vital resource for researchers, healthcare professionals, and students engaged in this dynamic field. The journal welcomes contributions spanning fundamental and clinical research, offering a platform for crucial knowledge exchange that is essential for advancing ocular health and function. With its commitment to open access, readers around the globe can freely access and build upon the wealth of information disseminated through its pages, ensuring that the latest developments in ophthalmology are available to all.

The Journal of Optometry, published by Elsevier, is a leading open access journal dedicated to advancing the field of optometry and vision science. With an ISSN of 1888-4296 and an E-ISSN of 1989-1342, this journal serves as a pivotal platform for researchers, practitioners, and academics alike to disseminate and engage with high-quality original research and review articles. As of 2023, the journal holds an impressive Q2 ranking in the Optometry category, demonstrating its influence and relevance, particularly as it ranks #2 out of 12 in the Health Professions - Optometry category on Scopus with an 87th percentile. Since becoming open access in 2008, the Journal of Optometry has prioritized accessibility and the exchange of ideas, enriching the scholarly community and enhancing practical application in clinical settings. The journal welcomes submissions that push the boundaries of ocular research, clinical practices, and the education of optometry professionals, making it an essential resource for anyone invested in the future of eye health.